Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Estee Lauder Companies Inc (EL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Estee Lauder Companies Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.66 (market cap $39.89B), while Estee Lauder Companies Inc trades at $83.78 (market cap $29.91B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Estee Lauder Companies Inc pays a 1.69% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | EL | |
|---|---|---|
Market Cap | $39.89B | $29.91B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $119.61 |
52-Week Low | $278.09 | $67.23 |
Enterprise Value | $38.15B | $36.08B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Estée Lauder (EL) trades at $82.66, up 0.82% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported negative net income of -$1.13B in 2025, though it has beaten EPS estimates in recent quarters. Revenue has declined from $17.7B in 2022 to $14.33B in 2025, while debt-to-asset ratio rose to 36.78%.
The outlook is mixed: analyst consensus is a Buy with a $90.60 price target, but high valuation ratios and profitability challenges pose risks. Positive sentiment from news highlights innovation and industry trends, yet financial performance and macroeconomic pressures remain headwinds for near-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →
